June 2012 Blog Posts (29)

Cancer is Still Leading Cause for Critical Illness Insurance Claims

According to findings published by the American Association for Critical Illness Insurance (AACII), cancer was last year (2011) the leading cause for critical illness insurance claims. Nearly half of all claims were for patients between ages 35 and 54. Stroke was the second leading cause followed by heart attack.

"Every year millions of Americans hear the dreaded words from a doctor, you have cancer or…


Added by Peter Hofland, PhD on June 27, 2012 at 6:00am — No Comments

New Partnership Paves the Way for Major Leap Forward in Total Cancer Care

Social and emotional support are critical components of complete cancer care. Recognizing this fact, the Greenville Hospital System announced the partnership between the Center for Integrative Oncology and Survivorship, and the Cancer Support Community (CSC) – one of the largest worldwide providers of social and emotional support for cancer patients and their caregivers.

"Research shows that social and…


Added by Peter Hofland, PhD on June 26, 2012 at 2:00pm — No Comments

A Personal Quest: Doctor Works on Improving Quality of Life for Patients with Brain Tumor Receiving Radiation Therapy

The Death of his first wife makes improving the Quality of Life (QoL) for patients with a brain tumor very personal for Mike Robbins, associate director of the Thomas K. Hearn Jr. Brain Tumor Research Center at Wake Forest Baptist Medical Center. Robbins knows all too well that the likely outcome when patients are diagnosed with brain tumors that are "high grade" may not always be positive.



Added by Peter Hofland, PhD on June 26, 2012 at 11:00am — No Comments

Florida Urologists Reviews Prostate Cancer PSA Screening and Treatment Options

Earlier today, Bert Vorstman, M.D., a Florida urologist with nearly 30 years expertise in prostate cancer diagnosis and treatment, launched a series of exclusive medical reports detailing information and misinformation about prostate cancer screening and treatment options, including myths and marketing related information behind.

Vorstman releases his…


Added by Peter Hofland, PhD on June 26, 2012 at 10:30am — No Comments

New Prostate Cancer Screening Option May Soon be Available in U.S.

A groundbreaking new prostate cancer screening test – approved by the Center for Devices and Radiological Health (CDRH) of the U.S. Food & Drug Administration (FDA) and currently available in Europe and Australia – may change the face of screening through its more accurate readings and reduction of false-positive results.

Prostate cancer remains the second…


Added by Peter Hofland, PhD on June 25, 2012 at 1:30pm — No Comments

Blood System Protein Complex May Protects Against Radiation Toxicity

Research published in Nature Medicine shows that boosting a protein pathway in the body's blood making system protects mice from otherwise fatal radiation poisoning. Scientists in the multi-institutional study – posted online by the journal on June 24, 2012 – say their findings open the potential for new treatments against radiation toxicity during cancer treatment or environmental…


Added by Peter Hofland, PhD on June 24, 2012 at 10:00am — No Comments

Researchers Identify Mutations in JAK3 gene in NK/T-cell lymphoma - a Promising Drug Target

Researchers at the Van Andel Institute have identified a potential drug target for NK/T-cell lymphoma, a type of cancer responsible for claiming the life of a close friend and fellow researcher.

A study authored by Bin Tean Teh, M.D., Ph.D., and published this week in Cancer Discovery, a journal of the American Association for…


Added by Peter Hofland, PhD on June 22, 2012 at 8:00am — No Comments

Trial Shows Breast Cancer Patients with HER2-positive Metastatic Breast Cancer Treated with Pertuzumab Live Longer

Results from the phase III CLEOPATRA study showed that women with HER2-positive metastatic breast cancer (mBC) lived significantly longer (overall survival) when treated with the combination of pertuzumab (Perjeta™, Genentech/Roche), trastuzumab (Herceptin®, Genentech/Roche) and docetaxel chemotherapy, compared to trastuzumab and docetaxel chemotherapy alone. in the Phase III . These data will be submitted for presentation at an upcoming medical meeting.…


Added by Peter Hofland, PhD on June 21, 2012 at 5:30pm — No Comments

ASCO Impact Report Shows Oncologists are Likely to Shift Patient Treatment Plans

The 2012 ASCO Impact Report, a survey of physicians and healthcare professionals attending the annual meeting of the American Society of Clinical Oncologists (ASCO), published by Encuity Research, the market research and analytics subsidiary of Campbell Alliance, revealed that this year's event had a significant impact on the treatment plans of…


Added by Peter Hofland, PhD on June 21, 2012 at 10:00am — No Comments

Candidate Drug Stops Cancer Cells and Regenerates Nerve Cells

Scientists at the Cincinnati Children's Hospital Medical Center have developed a small-molecule-inhibiting drug that in early laboratory cell tests stopped breast cancer cells from spreading and also promoted the growth of early nerve cells called neurites.

The research findings report were published online on June 22, 2012 in Chemistry & Biology. The scientists named their lead…


Added by Peter Hofland, PhD on June 21, 2012 at 9:30am — No Comments

Carfilzomib Receives Positive Vote from FDA's Oncologic Drugs Advisory Committee (ODAC)

The U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) determined by a vote of 11-0 [with 1 abstention] earlier today, that, in patients with relapsed and refractory multiple myeloma who have received at least two prior lines of therapy that included a proteasome inhibitor and an immunomodulatory agent (IMiD), the benefit-risk assessment is favorable for the use of carfilzomib (proposed brand name Kyprolis™).…


Added by Peter Hofland, PhD on June 20, 2012 at 2:30pm — No Comments

The Next Advancements in Cancer Drug Development: Antibody-Drug Conjugates

The annual meeting of the American Society of Clinical Oncology (ASCO) conference held June 1-5, 2012 in Chicago, IL. offered a wealth of new scientific and clinical data. It is expected that this year's event will have a significant impact on the patients treatment plans.

After reviewing this years meeting, a new type of targeted therapy was of particular interest to reviewer Daphna Halpern, Director of Oncology at…


Added by Peter Hofland, PhD on June 14, 2012 at 6:00am — No Comments

Study Intensifies First Strike at High-Risk Neuroblastoma in Children

An experimental treatment that combines intense chemotherapy with a radioactive isotope linked to synthesized neurotransmitter is being tested in newly diagnosed cases of high-risk neuroblastoma – a deadly, hard-to-cure childhood cancer.

The experimental radiopharmaceutical, 131I-MIBG, has already been tested in children with relapsed and resistant neuroblastoma, with encouraging results in reducing tumor size. This has prompted doctors in a new…


Added by Peter Hofland, PhD on June 12, 2012 at 9:00am — No Comments

Experimental Development: Encouraging Signs of Efficacy of BPM 31510

BPM 31510 targets the metabolic machinery of the cancer microenvironment to reverse the aerobic glycolytic phenotype of cancer cells also called the Warburg phenotype.  The Warburg phenotype has been related to the pathogenesis of schizophrenia, malignancy, metabolic syndrome x, autoimmune disease and neuronal degeneration.

The endogenous small molecule resident in mitochondria restores oxidative phosphorylation and confers re-capitulation of the BCL-2…


Added by Peter Hofland, PhD on June 12, 2012 at 5:00am — No Comments

Phase II study with Tivantinib (ARQ 197) Shows Positive Results in Previously Treated Hepatocellular Carcinoma (HCC)

Final results from a randomized, placebo-controlled, double-blind, phase II clinical trial with the selective MET inhibitor tivantinib (ARQ 197;  ArQule, Inc. and Daiichi Sankyo Company, Limited) as a single-agent, investigational, second-line treatment in hepatocellular carcinoma (HCC) shows positive results. The data was presented at the…


Added by Peter Hofland, PhD on June 11, 2012 at 4:00am — No Comments

New Quality Measures to Encourage Better Taking of Family Histories and Referral to Genetic Counseling: Community Oncologists Better at Documenting

Documenting a cancer patient’s family history (CFH) of cancer is important in establishing risk for primary and secondary cancer and identifying individuals who may be candidates for genetic counseling and genetic testing. Prior studies have demonstrated low rates of family history documentation and low referral rates for genetic counseling and genetic testing.

In 2011, the American Society for Clinical Oncology's (…


Added by Peter Hofland, PhD on June 6, 2012 at 7:00pm — No Comments

Routine Molecular Testing of Non-Small Cell Lung Cancers in Community Hospitals Is Feasible

A multicenter study in Germany reports that it is feasible to routinely conduct high-quality molecular analysis of non-small cell lung cancers (NSCLC) in local community hospitals that are not affiliated with academic medical centers. The study results, presented at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO), indicate that molecular testing can be made available to more patients, and in many cases,…


Added by Peter Hofland, PhD on June 5, 2012 at 7:30pm — No Comments

Oral Multi-kinase Inhibitor Regorafenib Effective for GISTs that Progress Due to Resistance to Standard Therapies

Results of an international Phase III trial demonstrate that the new targeted oral drug, regorafenib, which targets angiogenic, stromal and oncogenic receptor tyrosine kinase, can improve outcomes for patients with gastrointestinal stromal tumors (GIST) that progress due to resistance to other available treatment options, including imatinib (Gleevec®, Novartis) and sunitinib (…


Added by Peter Hofland, PhD on June 5, 2012 at 7:00pm — No Comments

Lower Levels of Radiation Therapy Can Increase Risk of Breast Cancer Among Young Women Treated for Childhood Cancer

A study finds that female survivors of childhood cancer treated with radiation to the chest had a high risk of developing breast cancer at a young age, comparable to that of BRCA1/2 mutation carriers. The findings also suggest that more survivors may be affected than previously thought. The results were presented at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO).



Added by Peter Hofland, PhD on June 5, 2012 at 6:30pm — No Comments

Trial Results Show BRAF Inhibitor Dabrafenib Delays Disease Progression Better than Standard Chemotherapy in Patients With Advanced Melanoma

A Phase III multicenter clinical trial finds that treatment with the investigational BRAF-targeted drug dabrafenib, an investigational, orally bioavailable inhibitor of the BRAF protein, reduced the risk of disease progression by 70% compared to standard…


Added by Peter Hofland, PhD on June 5, 2012 at 6:30pm — No Comments

Monthly Archives














Register for free to view all the Onco'Zine - The International Oncology Network content:


Onco'Zine is present here

Bookmark / Share



© 2017   Created by Peter Hofland, PhD.   Powered by

Badges  |  Report an Issue  |  Terms of Service

Find us on Google+